|
pubmed:abstractText |
Taxol is a relatively new antineoplastic agent whose classification as either vesicant, non-vesicant, or irritant remains under debate. This case study is presented to follow a large-volume Taxol extravasation. The article illustrates assessment, follow-up, intervention and outcome of this situation. This case suggests the drug is a vesicant with the potential to cause moderate soft tissue injury.
|
